4basebio (LON:4BB) Posts Quarterly Earnings Results

4basebio (LON:4BB) announced its quarterly earnings results on Wednesday. The company reported GBX (1.09) earnings per share (EPS) for the quarter, Digital Look Earnings reports. The business had revenue of GBX 169 million during the quarter.

4basebio Stock Up 6.9%

4BB stock traded up GBX 33 during midday trading on Thursday, reaching GBX 513. 3,083 shares of the company’s stock traded hands, compared to its average volume of 1,616. 4basebio has a 52 week low of GBX 420 and a 52 week high of GBX 1,150. The company has a market cap of £79.44 million, a price-to-earnings ratio of -5.18 and a beta of 1.09. The firm’s fifty day moving average price is GBX 496.49 and its 200-day moving average price is GBX 581.33. The company has a quick ratio of 3.52, a current ratio of 2.73 and a debt-to-equity ratio of 201.47.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.